This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Consequently, changes in salivary function can profoundly impair quality of life for cancer patients. We discuss approaches to quantify xerostomia in the clinic, including the advantages and limitations of validated quality-of-life instruments and approaches to directly measuring salivary function.
BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.
While invasive interventions can restore selected patients’ quality of life, pharmacologic therapies that are safe, well-tolerated and that reliably improve how patients feel and function remain an unmet need for patients with obstructive HCM.
Background Despite tremendous therapeutic advancements, a significant proportion of coronary artery disease patients suffer from refractory angina pectoris, that is, quality-of-life-compromising angina that is non-manageable with established pharmacological and interventional treatment options.
We propose that enhancing lymphatic function pharmacologically may be a novel and effective way to improve quality of life in patients with CKM syndrome by engaging multiple pathologies at once throughout the body.
highlight the misperception that pharmacologic heart rate lowering is beneficial, which has resulted in an overprescription of beta-blockers in HFpEF and AF. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
Other rehabilitation strategies that enhance cognitive reserve and pharmacological interventions are discussed about improving the quality of life in survivors. Management techniques reviewed include long-term cognitive health, such as endovascular coiling and surgical clipping.
Introduction Management of heart failure (HF) requires multidisciplinary, pharmacological and non-pharmacological strategies, one component of which is exercise training.
BackgroundCardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life.
This plaque narrows the blood vessels and reduces blood flow to the legs and feet, which may significantly impair physical function, walking performance and quality of life. Pharmacological and behavioral-based strategies often increase the smoking cessation rate in people with PAD, however, these strategies are underused.
New HCM Guidelines Updated recommendations in the guideline reflect recent evidence about HCM treatment and management including new forms of pharmacologic management; participation in vigorous recreational activities and competitive sports; and risk stratification for sudden cardiac death (SCD) with an emphasis on pediatric patients.
Pharmacological Interventions : Use of antihypertensive medications, lipid-lowering agents, and antidiabetic drugs. Overcoming status quo bias and embracing the latest evidence-based practices are essential steps toward delivering high-quality, personalized care in cardiometabolic medicine.
Furthermore, carrying excess weight can also have detrimental effects on mental health as individuals may experience low self-esteem, body image issues, depression, and a reduced quality of life. The Rise of Weight Loss Drugs The rise of weight loss drugs has brought with it a promising solution in the battle against obesity.
Pharmacological treatments: These can be divided into 2 groups Medications that improve quality of life (usually by relieving symptoms) and medications that can prolong life. Medications that improve quality of life in heart failure for example include diuretics.
Post-stroke mood disturbances may affect stroke survivors from returning to work, poorer quality of life (QOL), and stroke reoccurrence. Mood disturbances may be treated or prevented by pharmacological therapy, counseling, and education. Approximately 30-50% of post-stroke patients have emotional and mood disturbances (e.g.,
5+) support is effective in facilitating heart recovery, overall survival, and quality of life. A comprehensive platform of mechanical and pharmacological unloading is key. The objective of the study is to examine whether Impella 5.0/5.5
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content